<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01599104</url>
  </required_header>
  <id_info>
    <org_study_id>CLCZ696A1306</org_study_id>
    <nct_id>NCT01599104</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of LCZ696 in Comparison to Olmesartan in Japanese Patients With Essential Hypertension</brief_title>
  <official_title>A Multi-center, Randomized, Double-blind, Active-controlled, 8-week Study to Evaluate the Efficacy and Safety of LCZ696 in Comparison to Olmesartan in Japanese Patients With Essential Hypertension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study assessed the efficacy of LCZ696 in Japanese patients with essential hypertension
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2012</start_date>
  <completion_date type="Actual">April 2013</completion_date>
  <primary_completion_date type="Actual">April 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in Mean Sitting Systolic Blood Pressure (msSBP)</measure>
    <time_frame>Baseline, 8 weeks</time_frame>
    <description>Sitting BP measurements were performed at screening through the end of study at every visit. Four separate sitting BP were obtained with a full two-minute interval between measurements. The 4 measurements were summed and averaged, and then the baseline BP value was subtracted from the average value to get the change from baseline.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Mean 24-hour Ambulatory SBP (maSBP) at Week 8</measure>
    <time_frame>Baseline, 8 weeks</time_frame>
    <description>Ambulatory blood pressure monitoring (ABPM) over a 24-hour period was conducted at two time-points during the study in a subset of participants.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Mean Sitting Diastolic Blood Pressure (msDBP)</measure>
    <time_frame>Baseline, 8 weeks</time_frame>
    <description>Sitting BP measurement was performed at screening through the end of study at every visit. Four separate sitting BP were obtained with a full two-minute interval between measurement. The 4 measurements were summed and averaged, and then the baseline BP value was subtracted from the average value to get the change from baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving a Successful Response in Overall Blood Pressure Control at Week 8</measure>
    <time_frame>8 weeks</time_frame>
    <description>A successful response in overall BP control rate was defined as msSBP &lt; 140 mmHg and msDBP &lt;90 mmHg.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving a Successful msSBP Response</measure>
    <time_frame>8 weeks</time_frame>
    <description>Successful msSBP response was defined as &lt; 140 mmHg or ≥ 20 mmHg reduction from baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving a Successful msDBP Response</measure>
    <time_frame>8 weeks</time_frame>
    <description>Successfull msDBP response was defined as &lt;90 mmHg or ≥10 mmHg reduction from baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Mean 24-hour Ambulatory DBP (maDBP) at Week 8</measure>
    <time_frame>Baseline, 8 weeks</time_frame>
    <description>ABPM over a 24-hour period was conducted at two time-points during the study in a subset of participants.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in maSBP and maDBP for Daytime/Nighttime</measure>
    <time_frame>Baseline, 8 weeks</time_frame>
    <description>ABPM over a 24-hour period was conducted at two time-points during the study in a subset of participants.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Office Pulse Pressure</measure>
    <time_frame>Baseline, 8 weeks</time_frame>
    <description>Office pulse pressure was calculated as msSBP minus msDBP. Sitting blood pressure (BP) measurement was performed at screening through the end of study at every visit. Four separate sitting BP were obtained with a full two-minute interval between measurement. The 4 measurements were summed and then averaged to calculate the mean BP value. The baseline PP value was subtracted from the week 8 PP value to determine the change from baseline in PP.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Mean 24-hour Ambulatory Pulse Pressure</measure>
    <time_frame>Baseline, 8 weeks</time_frame>
    <description>Ambulatory pulse pressure was calculated as hourly ambulatory SBP minus hourly ambulatory DBP in a subset of participants.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With Adverse Events, Serious Adverse Events and Death</measure>
    <time_frame>8 weeks</time_frame>
    <description>Participants were monitored for adverse events, serious adverse events and deaths throughout the study.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">1161</enrollment>
  <condition>Essential Hypertension</condition>
  <arm_group>
    <arm_group_label>LCZ696 200 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LCZ696 200 mg tablet and placebo to both LCZ696 (1 tablet) and Olmesartan (1 capsule) tablet once daily for 8 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LCZ696 400 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LCZ696 200 mg tablet and a placebo to both LCZ696 (1 tablet) and Olmesartan (1 capsule) once daily for one week; then up-titrated to LCZ696 400 mg and placebo to Olmesartan (1 capsule) once daily for the remaining 7 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Olmesartan 20 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Olmesartan 20 mg capsule and placebo to LCZ696 (2 tablets) once daily for 8 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LCZ696</intervention_name>
    <description>200 mg (one tablet) or 400 mg (2 tablets of 200mg) once daily</description>
    <arm_group_label>LCZ696 200 mg</arm_group_label>
    <arm_group_label>LCZ696 400 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Olmesartan</intervention_name>
    <description>Olmesartan 20 mg capsule one daily</description>
    <arm_group_label>Olmesartan 20 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo to LCZ696 or Olmesartan</description>
    <arm_group_label>LCZ696 200 mg</arm_group_label>
    <arm_group_label>LCZ696 400 mg</arm_group_label>
    <arm_group_label>Olmesartan 20 mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with mild-to-moderate hypertension, untreated or currently taking
             antihypertensive therapy.

          -  Treated patients (using antihypertensive treatments within 4 weeks prior to Visit 1)
             must have an msSBP ≥ 150 mmHg and &lt; 180 mmHg at the randomization visit (Visit 201)
             and msSBP ≥140 mmHg &lt; 180 mmHg at the visit immediately proceeding Visit 201 (Visit
             102 or 103).

          -  Untreated patients (newly diagnosed with essential hypertension or having a history of
             hypertension but have not been taking any antihypertensive drugs for at least 4 weeks
             prior to Visit 1) must have an msSBP ≥ 150 mmHg and &lt; 180 mmHg at both Visit 1 and
             Visit 201.

          -  Patients must have an absolute difference of ≤15 mmHg in msSBP between Visit 201 and
             the immediately preceding visit;

        Exclusion Criteria:

          -  Severe hypertension (msDBP ≥110 mmHg and/or msSBP ≥ 180 mmHg).

          -  History of angioedema, drug-related or otherwise, as reported by the patient.

          -  History or evidence of a secondary form of hypertension, including but not limited to
             any of the following: renal parenchymal hypertension, renovascular hypertension
             (unilateral or bilateral renal artery stenosis), coarctation of the aorta, primary
             hyperaldosteronism, Cushing's disease, pheochromocytoma, polycystic kidney disease,
             and drug-induced hypertension.

          -  Patients who previously entered a LCZ696 study and had been randomized or enrolled
             into the active drug treatment epoch.

        Other protocol-defined inclusion/exclusion criteria may apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kamogawa-City</city>
        <state>Chiba</state>
        <zip>296-8602</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Chikushi-gun</city>
        <state>Fukuoka</state>
        <zip>811-1244</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Fukuoka-city</city>
        <state>Fukuoka</state>
        <zip>810-0014</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Fukuoka-city</city>
        <state>Fukuoka</state>
        <zip>810-0066</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Fukuoka-city</city>
        <state>Fukuoka</state>
        <zip>812-8582</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kitakyushu-city</city>
        <state>Fukuoka</state>
        <zip>800-0225</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kitakyushu-city</city>
        <state>Fukuoka</state>
        <zip>807-0856</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Asahikawa</city>
        <state>Hokkaido</state>
        <zip>078-8214</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sapporo-city</city>
        <state>Hokkaido</state>
        <zip>006-0811</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sapporo-city</city>
        <state>Hokkaido</state>
        <zip>062-0053</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sapporo-city</city>
        <state>Hokkaido</state>
        <zip>063-0842</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sapporo</city>
        <state>Hokkaido</state>
        <zip>003-0026</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sapporo</city>
        <state>Hokkaido</state>
        <zip>003-0825</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Amagasaki</city>
        <state>Hyogo</state>
        <zip>660-0814</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hitachi-city</city>
        <state>Ibaraki</state>
        <zip>317-0077</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kawasaki-city</city>
        <state>Kanagawa</state>
        <zip>210-0852</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Yokohama-city</city>
        <state>Kanagawa</state>
        <zip>231-0023</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Yokohama-city</city>
        <state>Kanagawa</state>
        <zip>236-0004</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kyotanabe-city</city>
        <state>Kyoto</state>
        <zip>610-0361</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kyoto-city</city>
        <state>Kyoto</state>
        <zip>615-0035</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kyoto-city</city>
        <state>Kyoto</state>
        <zip>615-8125</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kashihara-city</city>
        <state>Nara</state>
        <zip>634-8522</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ibadraki</city>
        <state>Osaka</state>
        <zip>567-0876</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Osaka-city</city>
        <state>Osaka</state>
        <zip>547-0013</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Toyonaka-city</city>
        <state>Osaka</state>
        <zip>560-0082</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ageo-city</city>
        <state>Saitama</state>
        <zip>362-8588</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Fujimino</city>
        <state>Saitama</state>
        <zip>356-0053</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hiki-Gun</city>
        <state>Saitama</state>
        <zip>355-0328</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Koshigaya city</city>
        <state>Saitama</state>
        <zip>343-0826</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Niiza-city</city>
        <state>Saitama</state>
        <zip>352-0014</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sakado</city>
        <state>Saitama</state>
        <zip>350-0202</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Tokorozawa-city</city>
        <state>Saitama</state>
        <zip>359-1161</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Shimotsuke-city</city>
        <state>Tochigi</state>
        <zip>329-0498</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bunkyo-ku</city>
        <state>Tokyo</state>
        <zip>113-0031</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bunkyo-ku</city>
        <state>Tokyo</state>
        <zip>113-8655</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Chiyoda-ku</city>
        <state>Tokyo</state>
        <zip>100-0005</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Edogawa-ku</city>
        <state>Tokyo</state>
        <zip>133-0061</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Edogawa-ku</city>
        <state>Tokyo</state>
        <zip>134-0084</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hachioji-city</city>
        <state>Tokyo</state>
        <zip>192-0918</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hachioji</city>
        <state>Tokyo</state>
        <zip>192-0046</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Katsushika-ku</city>
        <state>Tokyo</state>
        <zip>124-0024</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kiyose-city</city>
        <state>Tokyo</state>
        <zip>204-0021</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kunitachi</city>
        <state>Tokyo</state>
        <zip>186-0001</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Meguro-ku</city>
        <state>Tokyo</state>
        <zip>152-0031</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Minato-ku</city>
        <state>Tokyo</state>
        <zip>105-7390</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Minato-ku</city>
        <state>Tokyo</state>
        <zip>108-0075</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Nerima-ku</city>
        <state>Tokyo</state>
        <zip>177-0051</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ota-ku</city>
        <state>Tokyo</state>
        <zip>143-0023</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Shibuya-ku</city>
        <state>Tokyo</state>
        <zip>150-0002</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Shinagawa-ku</city>
        <state>Tokyo</state>
        <zip>141-0032</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Shinagawa-ku</city>
        <state>Tokyo</state>
        <zip>142-0053</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Shinagawa-ku</city>
        <state>Tokyo</state>
        <zip>142-0063</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Shinjuku-ku</city>
        <state>Tokyo</state>
        <zip>160-8582</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Tachikawa</city>
        <state>Tokyo</state>
        <zip>190-0013</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Taito</city>
        <state>Tokyo</state>
        <zip>111-0052</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Toshima-ku</city>
        <state>Tokyo</state>
        <zip>171-0021</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Fukuoka</city>
        <zip>814-0032</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Osaka</city>
        <zip>536-0008</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Osaka</city>
        <zip>550-0013</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Osaka</city>
        <zip>560-0005</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Saitama</city>
        <zip>337-0012</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>September 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 13, 2012</study_first_submitted>
  <study_first_submitted_qc>May 13, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 15, 2012</study_first_posted>
  <results_first_submitted>July 11, 2015</results_first_submitted>
  <results_first_submitted_qc>July 11, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 6, 2015</results_first_posted>
  <last_update_submitted>September 25, 2015</last_update_submitted>
  <last_update_submitted_qc>September 25, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 16, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Essential hypertension</keyword>
  <keyword>LCZ696</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Olmesartan</mesh_term>
    <mesh_term>Olmesartan Medoxomil</mesh_term>
    <mesh_term>LCZ 696</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The study consisted of 3 epochs: 1)screening, 2) single blind run-in and 3) double blind treatment. During the run-in epoch, eligible participants received placebo to both treatments for 2 to 4 weeks. After the run-in epoch, a total of 1161 eligible participants continued into the double blind treatment epoch for 8 weeks.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>LCZ696 200 mg</title>
          <description>LCZ696 200 mg tablet and a placebo tablet once daily for eight weeks</description>
        </group>
        <group group_id="P2">
          <title>LCZ696 400 mg</title>
          <description>LCZ696 200 mg tablet and a placebo tablet once daily for one week, then up-titrated to 400 mg once daily for the remaining 7 weeks</description>
        </group>
        <group group_id="P3">
          <title>Olmesartan 20 mg</title>
          <description>Olmesartan 20 mg tablet and a placebo tablet once daily for 8 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="387"/>
                <participants group_id="P2" count="385"/>
                <participants group_id="P3" count="389"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="371"/>
                <participants group_id="P2" count="371"/>
                <participants group_id="P3" count="363"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="14"/>
                <participants group_id="P3" count="26"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Technical Problems</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Non-compliance with study treatment</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="10"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="12"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>LCZ696 200 mg</title>
          <description>LCZ696 200 mg tablet and a placebo tablet once daily for eight weeks</description>
        </group>
        <group group_id="B2">
          <title>LCZ696 400 mg</title>
          <description>LCZ696 200 mg tablet and a placebo tablet once daily for one week, then up-titrated to 400 mg once daily for the remaining 7 weeks</description>
        </group>
        <group group_id="B3">
          <title>Olmesartan 20 mg</title>
          <description>Olmesartan 20 mg tablet and a placebo tablet once daily for 8 weeks</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="387"/>
            <count group_id="B2" value="385"/>
            <count group_id="B3" value="389"/>
            <count group_id="B4" value="1161"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57.9" spread="10.87"/>
                    <measurement group_id="B2" value="58.7" spread="10.50"/>
                    <measurement group_id="B3" value="59.6" spread="10.50"/>
                    <measurement group_id="B4" value="58.7" spread="10.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="123"/>
                    <measurement group_id="B2" value="117"/>
                    <measurement group_id="B3" value="103"/>
                    <measurement group_id="B4" value="343"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="264"/>
                    <measurement group_id="B2" value="268"/>
                    <measurement group_id="B3" value="286"/>
                    <measurement group_id="B4" value="818"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Mean Sitting Systolic Blood Pressure (msSBP)</title>
        <description>Sitting BP measurements were performed at screening through the end of study at every visit. Four separate sitting BP were obtained with a full two-minute interval between measurements. The 4 measurements were summed and averaged, and then the baseline BP value was subtracted from the average value to get the change from baseline.</description>
        <time_frame>Baseline, 8 weeks</time_frame>
        <population>Full Analysis Set (FAS): The full analysis set included all randomized participants who received study medication and had both baseline and post-baseline BP assessments.</population>
        <group_list>
          <group group_id="O1">
            <title>LCZ696 200 mg</title>
            <description>LCZ696 200 mg tablet and a placebo tablet once daily for eight weeks</description>
          </group>
          <group group_id="O2">
            <title>LCZ696 400 mg</title>
            <description>LCZ696 200 mg tablet and a placebo tablet once daily for one week, then up-titrated to 400 mg once daily for the remaining 7 weeks</description>
          </group>
          <group group_id="O3">
            <title>Olmesartan 20 mg</title>
            <description>Olmesartan 20 mg tablet and a placebo tablet once daily for 8 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Mean Sitting Systolic Blood Pressure (msSBP)</title>
          <description>Sitting BP measurements were performed at screening through the end of study at every visit. Four separate sitting BP were obtained with a full two-minute interval between measurements. The 4 measurements were summed and averaged, and then the baseline BP value was subtracted from the average value to get the change from baseline.</description>
          <population>Full Analysis Set (FAS): The full analysis set included all randomized participants who received study medication and had both baseline and post-baseline BP assessments.</population>
          <units>mmHg</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="387"/>
                <count group_id="O2" value="385"/>
                <count group_id="O3" value="389"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-18.21" spread="0.702"/>
                    <measurement group_id="O2" value="-20.18" spread="0.704"/>
                    <measurement group_id="O3" value="-13.20" spread="0.700"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Mean 24-hour Ambulatory SBP (maSBP) at Week 8</title>
        <description>Ambulatory blood pressure monitoring (ABPM) over a 24-hour period was conducted at two time-points during the study in a subset of participants.</description>
        <time_frame>Baseline, 8 weeks</time_frame>
        <population>The full analysis set included all randomized participants who received study medication, and had both baseline and post-baseline ABPM measurements. This outcome measure was analyzed in a subset of participants within each treatment group where n = 216 for the LCZ 200 mg group, n = 216 for the LCZ 400 mg group and n = 200 for the Olmesartan group.</population>
        <group_list>
          <group group_id="O1">
            <title>LCZ696 200 mg</title>
            <description>LCZ696 200 mg tablet and a placebo tablet once daily for eight weeks</description>
          </group>
          <group group_id="O2">
            <title>LCZ696 400 mg</title>
            <description>LCZ696 200 mg tablet and a placebo tablet once daily for one week, then up-titrated to 400 mg once daily for the remaining 7 weeks</description>
          </group>
          <group group_id="O3">
            <title>Olmesartan 20 mg</title>
            <description>Olmesartan 20 mg tablet and a placebo tablet once daily for 8 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Mean 24-hour Ambulatory SBP (maSBP) at Week 8</title>
          <description>Ambulatory blood pressure monitoring (ABPM) over a 24-hour period was conducted at two time-points during the study in a subset of participants.</description>
          <population>The full analysis set included all randomized participants who received study medication, and had both baseline and post-baseline ABPM measurements. This outcome measure was analyzed in a subset of participants within each treatment group where n = 216 for the LCZ 200 mg group, n = 216 for the LCZ 400 mg group and n = 200 for the Olmesartan group.</population>
          <units>mmHg</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="216"/>
                <count group_id="O2" value="216"/>
                <count group_id="O3" value="200"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-13.44" spread="0.445"/>
                    <measurement group_id="O2" value="-14.99" spread="0.445"/>
                    <measurement group_id="O3" value="-8.78" spread="0.462"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Mean Sitting Diastolic Blood Pressure (msDBP)</title>
        <description>Sitting BP measurement was performed at screening through the end of study at every visit. Four separate sitting BP were obtained with a full two-minute interval between measurement. The 4 measurements were summed and averaged, and then the baseline BP value was subtracted from the average value to get the change from baseline.</description>
        <time_frame>Baseline, 8 weeks</time_frame>
        <population>The full analysis set included all randomized participants who received study medication, and had both baseline and post-baseline BP measurements.</population>
        <group_list>
          <group group_id="O1">
            <title>LCZ696 200 mg</title>
            <description>LCZ696 200 mg tablet and a placebo tablet once daily for eight weeks</description>
          </group>
          <group group_id="O2">
            <title>LCZ696 400 mg</title>
            <description>LCZ696 200 mg tablet and a placebo tablet once daily for one week, then up-titrated to 400 mg once daily for the remaining 7 weeks</description>
          </group>
          <group group_id="O3">
            <title>Olmesartan 20 mg</title>
            <description>Olmesartan 20 mg tablet and a placebo tablet once daily for 8 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Mean Sitting Diastolic Blood Pressure (msDBP)</title>
          <description>Sitting BP measurement was performed at screening through the end of study at every visit. Four separate sitting BP were obtained with a full two-minute interval between measurement. The 4 measurements were summed and averaged, and then the baseline BP value was subtracted from the average value to get the change from baseline.</description>
          <population>The full analysis set included all randomized participants who received study medication, and had both baseline and post-baseline BP measurements.</population>
          <units>mmHg</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="387"/>
                <count group_id="O2" value="385"/>
                <count group_id="O3" value="389"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.76" spread="0.404"/>
                    <measurement group_id="O2" value="-8.79" spread="0.406"/>
                    <measurement group_id="O3" value="-5.91" spread="0.404"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Achieving a Successful Response in Overall Blood Pressure Control at Week 8</title>
        <description>A successful response in overall BP control rate was defined as msSBP &lt; 140 mmHg and msDBP &lt;90 mmHg.</description>
        <time_frame>8 weeks</time_frame>
        <population>The full analysis set included all randomized participants who received study medication, and had both baseline and post-baseline BP measurements.</population>
        <group_list>
          <group group_id="O1">
            <title>LCZ696 200 mg</title>
            <description>LCZ696 200 mg tablet and a placebo tablet once daily for eight weeks</description>
          </group>
          <group group_id="O2">
            <title>LCZ696 400 mg</title>
            <description>LCZ696 200 mg tablet and a placebo tablet once daily for one week, then up-titrated to 400 mg once daily for the remaining 7 weeks</description>
          </group>
          <group group_id="O3">
            <title>Olmesartan 20 mg</title>
            <description>Olmesartan 20 mg tablet and a placebo tablet once daily for 8 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving a Successful Response in Overall Blood Pressure Control at Week 8</title>
          <description>A successful response in overall BP control rate was defined as msSBP &lt; 140 mmHg and msDBP &lt;90 mmHg.</description>
          <population>The full analysis set included all randomized participants who received study medication, and had both baseline and post-baseline BP measurements.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="387"/>
                <count group_id="O2" value="385"/>
                <count group_id="O3" value="389"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.9"/>
                    <measurement group_id="O2" value="46.5"/>
                    <measurement group_id="O3" value="32.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Achieving a Successful msSBP Response</title>
        <description>Successful msSBP response was defined as &lt; 140 mmHg or ≥ 20 mmHg reduction from baseline.</description>
        <time_frame>8 weeks</time_frame>
        <population>The full analysis set included all randomized participants who received study medication, and had both baseline and post-baseline BP measurements.</population>
        <group_list>
          <group group_id="O1">
            <title>LCZ696 200 mg</title>
            <description>LCZ696 200 mg tablet and a placebo tablet once daily for eight weeks</description>
          </group>
          <group group_id="O2">
            <title>LCZ696 400 mg</title>
            <description>LCZ696 200 mg tablet and a placebo tablet once daily for one week, then up-titrated to 400 mg once daily for the remaining 7 weeks</description>
          </group>
          <group group_id="O3">
            <title>Olmesartan 20 mg</title>
            <description>Olmesartan 20 mg tablet and a placebo tablet once daily for 8 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving a Successful msSBP Response</title>
          <description>Successful msSBP response was defined as &lt; 140 mmHg or ≥ 20 mmHg reduction from baseline.</description>
          <population>The full analysis set included all randomized participants who received study medication, and had both baseline and post-baseline BP measurements.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="387"/>
                <count group_id="O2" value="385"/>
                <count group_id="O3" value="389"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57.9"/>
                    <measurement group_id="O2" value="63.1"/>
                    <measurement group_id="O3" value="42.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Achieving a Successful msDBP Response</title>
        <description>Successfull msDBP response was defined as &lt;90 mmHg or ≥10 mmHg reduction from baseline.</description>
        <time_frame>8 weeks</time_frame>
        <population>The full analysis set included all randomized participants who received study medication, and had both baseline and post-baseline BP measurements.</population>
        <group_list>
          <group group_id="O1">
            <title>LCZ696 200 mg</title>
            <description>LCZ696 200 mg tablet and a placebo tablet once daily for eight weeks</description>
          </group>
          <group group_id="O2">
            <title>LCZ696 400 mg</title>
            <description>LCZ696 200 mg tablet and a placebo tablet once daily for one week, then up-titrated to 400 mg once daily for the remaining 7 weeks</description>
          </group>
          <group group_id="O3">
            <title>Olmesartan 20 mg</title>
            <description>Olmesartan 20 mg tablet and a placebo tablet once daily for 8 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving a Successful msDBP Response</title>
          <description>Successfull msDBP response was defined as &lt;90 mmHg or ≥10 mmHg reduction from baseline.</description>
          <population>The full analysis set included all randomized participants who received study medication, and had both baseline and post-baseline BP measurements.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="387"/>
                <count group_id="O2" value="385"/>
                <count group_id="O3" value="389"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69.5"/>
                    <measurement group_id="O2" value="70.1"/>
                    <measurement group_id="O3" value="60.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Mean 24-hour Ambulatory DBP (maDBP) at Week 8</title>
        <description>ABPM over a 24-hour period was conducted at two time-points during the study in a subset of participants.</description>
        <time_frame>Baseline, 8 weeks</time_frame>
        <population>The full analysis set included all randomized participants who received study medication, and had both baseline and post-baseline ABPM measurements. This outcome measure was analyzed in a subset of participants within each treatment group where n = 216 for the LCZ 200 mg group, n = 216 for the LCZ 400 mg group and n = 200 for the Olmesartan group.</population>
        <group_list>
          <group group_id="O1">
            <title>LCZ696 200 mg</title>
            <description>LCZ696 200 mg tablet and a placebo tablet once daily for eight weeks</description>
          </group>
          <group group_id="O2">
            <title>LCZ696 400 mg</title>
            <description>LCZ696 200 mg tablet and a placebo tablet once daily for one week, then up-titrated to 400 mg once daily for the remaining 7 weeks</description>
          </group>
          <group group_id="O3">
            <title>Olmesartan 20 mg</title>
            <description>Olmesartan 20 mg tablet and a placebo tablet once daily for 8 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Mean 24-hour Ambulatory DBP (maDBP) at Week 8</title>
          <description>ABPM over a 24-hour period was conducted at two time-points during the study in a subset of participants.</description>
          <population>The full analysis set included all randomized participants who received study medication, and had both baseline and post-baseline ABPM measurements. This outcome measure was analyzed in a subset of participants within each treatment group where n = 216 for the LCZ 200 mg group, n = 216 for the LCZ 400 mg group and n = 200 for the Olmesartan group.</population>
          <units>mmHg</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="216"/>
                <count group_id="O2" value="216"/>
                <count group_id="O3" value="200"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.65" spread="0.295"/>
                    <measurement group_id="O2" value="-8.44" spread="0.295"/>
                    <measurement group_id="O3" value="-5.56" spread="0.307"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in maSBP and maDBP for Daytime/Nighttime</title>
        <description>ABPM over a 24-hour period was conducted at two time-points during the study in a subset of participants.</description>
        <time_frame>Baseline, 8 weeks</time_frame>
        <population>The full analysis set included all randomized participants who received study medication, and had both baseline and post-baseline ABPM measurements. This outcome measure was analyzed in a subset of participants within each treatment group where n = 216 for the LCZ 200 mg group, n = 216 for the LCZ 400 mg group and n = 200 for the Olmesartan group.</population>
        <group_list>
          <group group_id="O1">
            <title>LCZ696 200 mg</title>
            <description>LCZ696 200 mg tablet and a placebo tablet once daily for eight weeks</description>
          </group>
          <group group_id="O2">
            <title>LCZ696 400 mg</title>
            <description>LCZ696 200 mg tablet and a placebo tablet once daily for one week, then up-titrated to 400 mg once daily for the remaining 7 weeks</description>
          </group>
          <group group_id="O3">
            <title>Olmesartan 20 mg</title>
            <description>Olmesartan 20 mg tablet and a placebo tablet once daily for 8 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in maSBP and maDBP for Daytime/Nighttime</title>
          <description>ABPM over a 24-hour period was conducted at two time-points during the study in a subset of participants.</description>
          <population>The full analysis set included all randomized participants who received study medication, and had both baseline and post-baseline ABPM measurements. This outcome measure was analyzed in a subset of participants within each treatment group where n = 216 for the LCZ 200 mg group, n = 216 for the LCZ 400 mg group and n = 200 for the Olmesartan group.</population>
          <units>mmHg</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="216"/>
                <count group_id="O2" value="216"/>
                <count group_id="O3" value="200"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>maSBP daytime</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-12.60" spread="0.747"/>
                    <measurement group_id="O2" value="-14.44" spread="0.747"/>
                    <measurement group_id="O3" value="-7.87" spread="0.776"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>maSBP nighttime</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-15.13" spread="0.747"/>
                    <measurement group_id="O2" value="-16.09" spread="0.747"/>
                    <measurement group_id="O3" value="-10.65" spread="0.776"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>maDBP daytime</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.01" spread="0.506"/>
                    <measurement group_id="O2" value="-8.00" spread="0.506"/>
                    <measurement group_id="O3" value="-4.95" spread="0.526"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>maDBP nighttime</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.82" spread="0.506"/>
                    <measurement group_id="O2" value="-9.42" spread="0.506"/>
                    <measurement group_id="O3" value="-6.79" spread="0.526"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Office Pulse Pressure</title>
        <description>Office pulse pressure was calculated as msSBP minus msDBP. Sitting blood pressure (BP) measurement was performed at screening through the end of study at every visit. Four separate sitting BP were obtained with a full two-minute interval between measurement. The 4 measurements were summed and then averaged to calculate the mean BP value. The baseline PP value was subtracted from the week 8 PP value to determine the change from baseline in PP.</description>
        <time_frame>Baseline, 8 weeks</time_frame>
        <population>The full analysis set included all randomized participants who received study medication, and had both baseline and post-baseline BP measurements.</population>
        <group_list>
          <group group_id="O1">
            <title>LCZ696 200 mg</title>
            <description>LCZ696 200 mg tablet and a placebo tablet once daily for eight weeks</description>
          </group>
          <group group_id="O2">
            <title>LCZ696 400 mg</title>
            <description>LCZ696 200 mg tablet and a placebo tablet once daily for one week, then up-titrated to 400 mg once daily for the remaining 7 weeks</description>
          </group>
          <group group_id="O3">
            <title>Olmesartan 20 mg</title>
            <description>Olmesartan 20 mg tablet and a placebo tablet once daily for 8 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Office Pulse Pressure</title>
          <description>Office pulse pressure was calculated as msSBP minus msDBP. Sitting blood pressure (BP) measurement was performed at screening through the end of study at every visit. Four separate sitting BP were obtained with a full two-minute interval between measurement. The 4 measurements were summed and then averaged to calculate the mean BP value. The baseline PP value was subtracted from the week 8 PP value to determine the change from baseline in PP.</description>
          <population>The full analysis set included all randomized participants who received study medication, and had both baseline and post-baseline BP measurements.</population>
          <units>mmHg</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="387"/>
                <count group_id="O2" value="385"/>
                <count group_id="O3" value="389"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.49" spread="0.471"/>
                    <measurement group_id="O2" value="-11.30" spread="0.472"/>
                    <measurement group_id="O3" value="-7.34" spread="0.470"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Mean 24-hour Ambulatory Pulse Pressure</title>
        <description>Ambulatory pulse pressure was calculated as hourly ambulatory SBP minus hourly ambulatory DBP in a subset of participants.</description>
        <time_frame>Baseline, 8 weeks</time_frame>
        <population>The full analysis set included all randomized participants who received study medication, and had both baseline and post-baseline ABPM measurements. This outcome measure was analyzed in a subset of participants within each treatment group where n = 216 for the LCZ 200 mg group, n = 216 for the LCZ 400 mg group and n = 200 for the Olmesartan group.</population>
        <group_list>
          <group group_id="O1">
            <title>LCZ696 200 mg</title>
            <description>LCZ696 200 mg tablet and a placebo tablet once daily for eight weeks</description>
          </group>
          <group group_id="O2">
            <title>LCZ696 400 mg</title>
            <description>LCZ696 200 mg tablet and a placebo tablet once daily for one week, then up-titrated to 400 mg once daily for the remaining 7 weeks</description>
          </group>
          <group group_id="O3">
            <title>Olmesartan 20 mg</title>
            <description>Olmesartan 20 mg tablet and a placebo tablet once daily for 8 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Mean 24-hour Ambulatory Pulse Pressure</title>
          <description>Ambulatory pulse pressure was calculated as hourly ambulatory SBP minus hourly ambulatory DBP in a subset of participants.</description>
          <population>The full analysis set included all randomized participants who received study medication, and had both baseline and post-baseline ABPM measurements. This outcome measure was analyzed in a subset of participants within each treatment group where n = 216 for the LCZ 200 mg group, n = 216 for the LCZ 400 mg group and n = 200 for the Olmesartan group.</population>
          <units>mmHg</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="216"/>
                <count group_id="O2" value="216"/>
                <count group_id="O3" value="200"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.79" spread="0.208"/>
                    <measurement group_id="O2" value="-6.57" spread="0.207"/>
                    <measurement group_id="O3" value="-3.20" spread="0.216"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With Adverse Events, Serious Adverse Events and Death</title>
        <description>Participants were monitored for adverse events, serious adverse events and deaths throughout the study.</description>
        <time_frame>8 weeks</time_frame>
        <population>Safety Set. The safety set included aqll participants who had received study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>LCZ696 200 mg</title>
            <description>LCZ696 200 mg tablet and a placebo tablet once daily for eight weeks</description>
          </group>
          <group group_id="O2">
            <title>LCZ696 400 mg</title>
            <description>LCZ696 200 mg tablet and a placebo tablet once daily for one week, then up-titrated to 400 mg once daily for the remaining 7 weeks</description>
          </group>
          <group group_id="O3">
            <title>Olmesartan 20 mg</title>
            <description>Olmesartan 20 mg tablet and a placebo tablet once daily for 8 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Adverse Events, Serious Adverse Events and Death</title>
          <description>Participants were monitored for adverse events, serious adverse events and deaths throughout the study.</description>
          <population>Safety Set. The safety set included aqll participants who had received study medication.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="387"/>
                <count group_id="O2" value="385"/>
                <count group_id="O3" value="389"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Adverse Events (serious and non-serious)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="135"/>
                    <measurement group_id="O2" value="136"/>
                    <measurement group_id="O3" value="152"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Seroius Adverse Events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Deaths</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>LCZ696 200 mg</title>
          <description>LCZ696 200 mg tablet and a placebo tablet once daily for eight weeks</description>
        </group>
        <group group_id="E2">
          <title>LCZ696 400 mg</title>
          <description>LCZ696 200 mg tablet and a placebo tablet once daily for one week, then up-titrated to 400 mg once daily for the remaining 7 weeks</description>
        </group>
        <group group_id="E3">
          <title>Olmesartan 20 mg</title>
          <description>Olmesartan 20 mg tablet and a placebo tablet once daily for 8 weeks</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="387"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="385"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="389"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>ARTERIOSCLEROSIS CORONARY ARTERY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="385"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="389"/>
              </event>
              <event>
                <sub_title>SUPRAVENTRICULAR TACHYCARDIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="385"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="389"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>CATARACT</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="385"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="389"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>BILE DUCT STONE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="385"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="389"/>
              </event>
              <event>
                <sub_title>HEPATOBILIARY DISEASE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="385"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="389"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>RADIUS FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="385"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="389"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>ALANINE AMINOTRANSFERASE INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="385"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="389"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>OSTEOARTHRITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="385"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="389"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>CEREBRAL INFARCTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="385"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="389"/>
              </event>
              <event>
                <sub_title>SUBARACHNOID HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="387"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="385"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="389"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2</frequency_threshold>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="48" subjects_at_risk="387"/>
                <counts group_id="E2" subjects_affected="47" subjects_at_risk="385"/>
                <counts group_id="E3" subjects_affected="46" subjects_at_risk="389"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>NASOPHARYNGITIS</sub_title>
                <counts group_id="E1" subjects_affected="48" subjects_at_risk="387"/>
                <counts group_id="E2" subjects_affected="47" subjects_at_risk="385"/>
                <counts group_id="E3" subjects_affected="46" subjects_at_risk="389"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Study Director</name_or_title>
      <organization>Novartis Pharmaceuticals</organization>
      <phone>+1 (862) 778-8300</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

